V710 (30 µg) with MAA + V710 (30 µg) without MAA
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Staphylococcal Infections
Conditions
Staphylococcal Infections
Trial Timeline
Sep 1, 2006 → Oct 1, 2007
NCT ID
NCT01324440About V710 (30 µg) with MAA + V710 (30 µg) without MAA
V710 (30 µg) with MAA + V710 (30 µg) without MAA is a phase 1 stage product being developed by Merck for Staphylococcal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01324440. Target conditions include Staphylococcal Infections.
What happened to similar drugs?
4 of 5 similar drugs in Staphylococcal Infections were approved
Approved (4) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01324440 | Phase 1 | Completed |
Competing Products
20 competing products in Staphylococcal Infections